Affibody Overview

  • Founded
  • 1998

  • Status
  • Private

  • Employees
  • 113

  • Latest Deal Type
  • Debt

  • Latest Deal Amount
  • $21M

  • Investors
  • 3

Affibody General Information


Operator of a private clinical-stage biopharma company intended to develop protein-based drugs. The company engages in the research and development of drugs and monoclonal antibodies through its therapeutic programs that target psoriasis and B-cell drove autoimmune diseases respectively, enabling doctors to get access to therapies that improve the lives of patients with serious diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • Scheeles väg 2
  • 171 65 Solna
  • Sweden
+46 08-598 000 00

Affibody Timeline

Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Affibody Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Debt - General 22-Dec-2022 $21M 00000 Completed Profitable
6. Secondary Transaction - Private 01-Feb-2021 000.00 Completed Profitable
5. Later Stage VC 08-Mar-2018 000.00 000.00 Completed Profitable
4. Secondary Transaction - Private 01-Jan-2014 000.00 Completed Profitable
3. Later Stage VC 30-Mar-2007 000.00 000.00 Completed Generating Revenue
2. Early Stage VC 03-Oct-2001 $28M $28M Completed Startup
1. Early Stage VC 30-Jun-2000 Completed Startup
To view Affibody’s complete valuation and funding history, request access »

Affibody Patents

Affibody Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020380524-A1 New process of extracting protein Pending 08-Nov-2019 000000000
CA-3160027-A1 New process of extracting protein Pending 08-Nov-2019 000000000
EP-4055027-A1 New process of extracting protein Pending 08-Nov-2019 000000000
US-20220411743-A1 New process of extracting protein Pending 08-Nov-2019 000000000
US-20220389066-A1 Polypeptides Pending 05-Nov-2019 C07K14/435
To view Affibody’s complete patent history, request access »

Affibody Executive Team (18)

Name Title Board Seat Contact Info
David Bejker Chief Executive Officer & President
Camilla Danell Chief Financial Officer
Fredrik Frejd Ph.D Chief Scientific Officer
Caroline Ekblad Ph.D Director Alliance and IP Management
Birger Jansson Director, Research
You’re viewing 5 of 18 executive team members. Get the full list »

Affibody Board Members (10)

Name Representing Role Since
Anders Martin-Löf Self Board Member 000 0000
Camilla Sønderby Self Board Member 000 0000
Gillian Cannon Ph.D Affibody Board Member 000 0000
Jakob Lindberg MD Self Board Member 000 0000
Jonathan Knowles Ph.D Self Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Affibody Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Affibody Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Investor PE/Buyout Minority 000 0000 000000 0
Ingvar Kamprad Angel (individual) Minority 000 0000 000000 0
Lage Jonason Angel (individual) Minority 000 0000 000000 0
To view Affibody’s complete investors history, request access »

Affibody Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 000000 29-Jun-2001 0000000000 Other Healthcare Technology Systems
To view Affibody’s complete acquisitions history, request access »